Erythropoietin modulates bone marrow stromal cell differentiation

Abstract

Erythropoietin is essential for bone marrow erythropoiesis and erythropoietin receptor on non-erythroid cells including bone marrow stromal cells suggests systemic effects of erythropoietin. Tg6 mice with chronic erythropoietin overexpression have a high hematocrit, reduced trabecular and cortical bone and bone marrow adipocytes, and decreased bone morphogenic protein 2 driven ectopic bone and adipocyte formation. Erythropoietin treatment (1 200 IU·kg^–1) for 10 days similarly exhibit increased hematocrit, reduced bone and bone marrow adipocytes without increased osteoclasts, and reduced bone morphogenic protein signaling in the bone marrow. Interestingly, endogenous erythropoietin is required for normal differentiation of bone marrow stromal cells to osteoblasts and bone marrow adipocytes. ΔEpoR_E mice with erythroid restricted erythropoietin receptor exhibit reduced trabecular bone, increased bone marrow adipocytes, and decreased bone morphogenic protein 2 ectopic bone formation. Erythropoietin treated ΔEpoR_E mice achieved hematocrit similar to wild-type mice without reduced bone, suggesting that bone reduction with erythropoietin treatment is associated with non-erythropoietic erythropoietin response. Bone marrow stromal cells from wild-type, Tg6, and ΔEpoR_E-mice were transplanted into immunodeficient mice to assess development into a bone/marrow organ. Like endogenous bone formation, Tg6 bone marrow cells exhibited reduced differentiation to bone and adipocytes indicating that high erythropoietin inhibits osteogenesis and adipogenesis, while ΔEpoR_E bone marrow cells formed ectopic bones with reduced trabecular regions and increased adipocytes, indicating that loss of erythropoietin signaling favors adipogenesis at the expense of osteogenesis. In summary, endogenous erythropoietin signaling regulates bone marrow stromal cell fate and aberrant erythropoietin levels result in their impaired differentiation.

References

[1] Zhang Y et al. Erythropoietin action in stress response, tissue maintenance and metabolism. Int. J. Mol. Sci., 2014, 15:10296-10333

[2] Lin CS, Lim SK, D’Agati V, Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev., 1996, 10:154-164

[3] Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell, 1995, 83:59-67

[4] Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus. Med. Hemother, 2013, 40:302-309

[5] Beleslin-Cokic BB et al. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood, 2004, 104:2073-2080

[6] Yu X et al. Erythropoietin receptor signalling is required for normal brain development. Development, 2002, 129:505-516

[7] Ogilvie M et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J. Biol. Chem., 2000, 275:39754-39761

[8] Teng R et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat. Commun., 2011, 2

[9] Choi D et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J. Exp. Med, 2010, 207:2831-2842

[10] Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells, 2001, 19:180-192

[11] James AW. Review of signaling pathways governing MSC osteogenic and adipogenic differentiation. Sci. (Cairo), 2013, 2013:684736

[12] Schwartz AV et al. Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults. J. Clin. Endocrinol. Metab., 2013, 98:2294-2300

[13] Shen W et al. MRI-measured pelvic bone marrow adipose tissue is inversely related to DXA-measured bone mineral in younger and older adults. Eur. J. Clin. Nutr., 2012, 66:983-988

[14] Justesen J et al. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology, 2001, 2:165-171

[15] Compston JE et al. Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: global longitudinal study of osteoporosis in women (GLOW). Calcif. Tissue Int., 2014, 94:223-231

[16] Sheu Y et al. Vertebral bone marrow fat, bone mineral density and diabetes: The Osteoporotic Fractures in Men (MrOS) study. Bone, 2017, 97:299-305

[17] Crockett JC, Rogers MJ, Coxon FP, Hocking LJ, Helfrich MH. Bone remodelling at a glance. J. Cell Sci., 2011, 124:991-998

[18] Shiozawa Y et al. Erythropoietin couples hematopoiesis with bone formation. PLoS ONE, 2010, 5

[19] Singbrant S et al. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood, 2011, 117:5631-5642

[20] Wan L et al. EPO promotes bone repair through enhanced cartilaginous callus formation and angiogenesis. PloS ONE, 2014, 9

[21] Chen S, Li J, Peng H, Zhou J, Fang H. Administration of erythropoietin exerts protective effects against glucocorticoid-induced osteonecrosis of the femoral head in rats. Int. J. Mol. Med., 2014, 33:840-848

[22] Hiram-Bab S et al. Erythropoietin directly stimulates osteoclast precursors and induces bone loss. FASEB J., 2015, 29:1890-1900

[23] Ruschitzka FT et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc. Natl Acad. Sci. USA, 2000, 97:11609-11613

[24] Suzuki N et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood, 2002, 100:2279-2288

[25] Alnaeeli M et al. Erythropoietin signaling: a novel regulator of white adipose tissue inflammation during diet-induced obesity. Diabetes, 2014, 63:2415-2431

[26] Tachi K et al. Enhancement of bone morphogenetic protein-2-induced ectopic bone formation by transforming growth factor-beta1. Tissue Eng. Part A, 2011, 17:597-606

[27] Hata K et al. Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis. Mol. Biol. Cell, 2003, 14:545-555

[28] Jin W et al. Schnurri-2 controls BMP-dependent adipogenesis via interaction with Smad proteins. Dev. Cell, 2006, 10:461-471

[29] Nemeth, K., Mayer, B., Sworder, B. J., Kuznetsov, S. A. & Mezey, E. A practical guide to culturing mouse and human bone marrow stromal cells. Curr. Protoc. Immunol. 102, 22F.12 (2013).

[30] Anjos-Afonso, F. & Bonnet, D. Isolation, culture, and differentiation potential of mouse marrow stromal cells. Curr. Protoc. Stem Cell Biol. (2008). (Chapter 2, Unit 2B.3.1–2B.3.11).

[31] Robey PG, Kuznetsov SA, Riminucci M, Bianco P. Bone marrow stromal cell assays: in vitro and in vivo. Methods Mol. Biol., 2014, 1130:279-293

[32] Tong Q, Tsai J, Tan G, Dalgin G, Hotamisligil GS. Interaction between GATA and the C/EBP family of transcription factors is critical in GATA-mediated suppression of adipocyte differentiation. Mol. Cell. Biol., 2005, 25:706-715

[33] Zhang, Y., Rogers, H. M., Zhang, X. & Noguchi, C. T. Sex difference in mouse metabolic response to erythropoietin. FASEB J. 31, 2661–2673 (2017).

[34] Glatt V, Canalis E, Stadmeyer L, Bouxsein ML. Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J. Bone Miner. Res., 2007, 22:1197-1207

[35] Shu L et al. High-fat diet causes bone loss in young mice by promoting osteoclastogenesis through alteration of the bone marrow environment. Calcif. Tissue Int, 2015, 96:313-323

[36] Cohen A et al. Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J. Clin. Endocrinol. Metab., 2013, 98:2562-2572

[37] Charles JF et al. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J. Clin. Investig., 2012, 122:4592-4605

[38] Cao JJ, Gregoire BR, Shen CL. A high-fat diet decreases bone mass in growing mice with systemic chronic inflammation induced by low-dose, slow-release lipopolysaccharide pellets. J. Nutr., 2017, 147:1909-1916

[39] Foskett A, Alnaeeli M, Wang L, Teng R, Noguchi CT. The effects of erythropoietin dose titration during high-fat diet-induced obesity. J. Biomed. Biotechnol., 2011, 2011:373781

[40] Griffith JF et al. Bone marrow fat content in the elderly: a reversal of sex difference seen in younger subjects. J. Magn. Reson. Imaging., 2012, 36:225-230

[41] Rauner M et al. Increased EPO levels are associated with bone loss in mice lacking PHD2 in EPO-producing cells. J. Bone Min. Res, 2016, 31:1877-1887

[42] Kugimiya F et al. Involvement of endogenous bone morphogenetic protein (BMP) 2 and BMP6 in bone formation. J. Biol. Chem., 2005, 280:35704-35712

[43] Champagne CM, Takebe J, Offenbacher S, Cooper LF. Macrophage cell lines produce osteoinductive signals that include bone morphogenetic protein-2. Bone, 2002, 30:26-31

[44] Vukicevic S, Grgurevic L. BMP-6 and mesenchymal stem cell differentiation. Cytokine Growth Factor Rev., 2009, 20:441-448

[45] Mi M et al. Chondrocyte BMP2 signaling plays an essential role in bone fracture healing. Gene, 2013, 512:211-218

[46] Lifshitz L, Tabak G, Gassmann M, Mittelman M, Neumann D. Macrophages as novel target cells for erythropoietin. Haematologica, 2010, 95:1823-1831

[47] Patel JJ et al. Dual delivery of EPO and BMP2 from a novel modular poly-varepsilon-caprolactone construct to increase the bone formation in prefabricated bone flaps. Tissue Eng. Part C. Methods, 2015, 21:889-897

[48] Sun H, Jung Y, Shiozawa Y, Taichman RS, Krebsbach PH. Erythropoietin modulates the structure of bone morphogenetic protein 2-engineered cranial bone. Tissue Eng. Part A, 2012, 18:2095-2105

[49] Tong Q et al. Function of GATA transcription factors in preadipocyte-adipocyte transition. Science, 2000, 290:134-138

[50] Rankin EB et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell, 2012, 149:63-74

[51] Rolfing JH et al. The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dose-dependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways. Stem Cell Rev., 2014, 10:69-78

[52] Kim J et al. Erythropoietin mediated bone formation is regulated by mTOR signaling. J. Cell Biochem., 2012, 113:220-228

[53] Li CJ et al. MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J. Clin. Investig., 2015, 125:1509-1522

[54] Sui B et al. Mesenchymal progenitors in osteopenias of diverse pathologies: differential characteristics in the common shift from osteoblastogenesis to adipogenesis. Sci. Rep., 2016, 6

[55] Jing H et al. Suppression of EZH2 prevents the shift of osteoporotic MSC fate to adipocyte and enhances bone formation during osteoporosis. Mol. Ther., 2016, 24:217-229

[56] Tavassoli M. Ultrastructural development of bone marrow adipose cell. Acta Anat. (Basel), 1976, 94:65-77

[57] Suchacki KJ, Cawthorn WP, Rosen CJ. Bone marrow adipose tissue: formation, function and regulation. Curr. Opin. Pharm., 2016, 28:50-56

[58] Gao Y et al. Magnetic resonance imaging-measured bone marrow adipose tissue area is inversely related to cortical bone area in children and adolescents aged 5–18 years. J. Clin. Densitom., 2015, 18:203-208

[59] Scheller EL et al. Use of osmium tetroxide staining with microcomputerized tomography to visualize and quantify bone marrow adipose tissue in vivo. Methods Enzym., 2014, 537:123-139

[60] Bakker AD, Klein-Nulend J. Osteoblast isolation from murine calvaria and long bones. Methods Mol. Biol., 2012, 816:19-29

Funding

This work was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases and the Intramural Research Program of the National Institute of Dental and Craniofacial Research at the National Institutes of Health.